摘要
目的:探讨匹多莫德联合孟鲁司特对闭塞性细支气管炎患儿T细胞亚群的影响。方法:52例闭塞性细支气管炎患儿随机分为观察组和对照组各26例。在常规治疗基础上,对照组加用孟鲁司特治疗,观察组在对照组基础上再加用匹多莫德。观察两组患儿的临床疗效,治疗后症状(气促、喘憋、咳嗽)、体征(哮鸣音、湿啰音)的缓解或消失时间和住院时间,比较两组患儿治疗前后T细胞亚群变化。结果:治疗后,观察组显效率(80.77%)显著高于对照组(P<0.05);观察组患儿症状、体征的消失时间和住院时间均短于对照组(P<0.05)。治疗后,两组CD4+、CD4+/CD8+均较治疗前升高,CD8+则较前下降(P<0.05);且观察组均优于对照组(P<0.05)。两组药品不良反应发生率差异无统计学意义(P>0.05)。结论:匹多莫德联合孟鲁司特治疗闭塞性细支气管炎患儿,能够有效改善患儿T细胞亚群,迅速改善临床症状、体征,有较好的治疗效果。
Objective： To observe the influence of pidotimod combined montelukast with on T cell subsets in children with bronchiolitis obliterans. Methods： 52 cases of children with bronchiolitis obliterans were ramdomly divided into observation group（ 26 cases） and control group（ 26 cases）. The control group was given montelukast on the basis of the conventional treatment,the observation group was given pidotimod on the basis of the control group. Efficacy after treatment,disappear time of symptoms after treatment（ shortness of breath ease,wheezing disappeared,cough disappears）,signs（ wheeze disappeared,auscultation disappear） and length of stay,and T cell subsets of two groups were compared.Results： After the treatment,the effective rate of the observation group（ 80. 77%） was significantly higher than that of control group（ P 〈 0. 05）; the disappearance time of symptoms,signs and hospital stays of observation group were shorter than those in control group（ P 〈 0. 05）. After treatment,CD4~＋,CD4~＋/ CD8~＋ in two groups were higher than before treatment,though CD8~＋ were decreased（ P 〈 0. 05）; and the values in observation group were superior to the control group（ P 〈0. 05）. The incidence of adverse reactions of two groups had not statistically significant（ P 〉 0. 05）. Conclusion： Pidotimod combined with montelukast has a good effect for children with bronchiolitis obliterans,it can improve T cell subsets,improve the symptoms and signs quickly,and has a good therapeutic effect.
出处
《药物流行病学杂志》
CAS
2016年第8期473-476,共4页
Chinese Journal of Pharmacoepidemiology
基金
河北省沧州市科技计划项目(编号:131302095)
